Through phosphoproteomics analysis of lapatinib-sensitive (SKBR3) and lapatinib-resistant (SKBR3-LR) breast cell lines, p21-activated kinase 2 (PAK2) was identified as an effective therapeutic target to overcome acquired lapatinib resistance in HER2-positive breast cancer.89 Here, PAK2 is linked to breast cancer.